Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

INTRODUCTION: Dupilumab, a fully human anti-IL-4Rα monoclonal antibody, inhibits signaling of both interleukin (IL)-4 and IL-13, which are key drivers of type 2-mediated inflammation. Dupilumab is approved in the EU, USA, and other countries for the treatment of adults with inadequately controlled m...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Adv Ther
Autores principales: Busse, William W., Maspero, Jorge F., Rabe, Klaus F., Papi, Alberto, Wenzel, Sally E., Ford, Linda B., Pavord, Ian D., Zhang, Bingzhi, Staudinger, Heribert, Pirozzi, Gianluca, Amin, Nikhil, Akinlade, Bolanle, Eckert, Laurent, Chao, Jingdong, Graham, Neil M. H., Teper, Ariel
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Healthcare 2018
Materias:
Study Protocol
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5960488/
https://ncbi.nlm.nih.gov/pubmed/29725983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-018-0702-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares